-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97

Benzinga·08/07/2026 20:09:34
Listen to the news
Citigroup analyst Samantha Semenkow maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $100 to $97.